Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Descriptionsort icon Status Initial Date
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Unlocking the promise of genome editing to deliver life-changing medicines. Private 2013 View Profile
<a href="/venture-capital/all-companies/moderna">moderna</a> Pioneering an entirely new drug modality using messenger RNA therapeutics™. Private 2010 View Profile
<a href="/venture-capital/all-companies/permeon-biologics-inc">Permeon Biologics Inc.</a> Pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Private 2011 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Nanomedicine platform company developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. Public 2008 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Private 2012 View Profile
<a href="/venture-capital/all-companies/receptos-inc">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. Public 2009 View Profile
<a href="/venture-capital/all-companies/celexion-llc">Celexion LLC</a> Developing powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. Private 2009 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Private 2008 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing a pipeline of innovative treatments for bladder diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Public 2006 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Advancing the science and technology of corneal crosslinking. Private 2009 View Profile
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming medicine with ProNutrein™ products, protein nutrients identified in the human diet, for the dietary management of disease. Private 2010 View Profile